reports
- Patrik Ling
Vimian (Buy, TP: SEK128.00) - Set for some seasonal softness
We expect continued tough comparables and margins to remain under pressure in Q3. In our view, tax changes could boost US acquisitions before year-end. We have made minor estimate changes for 2021–2022, and reiterate our BUY and SEK128 target price.
- Patrik Ling
Vimian - Initiation of coverage - Paw-some profits
Vimian is a Swedish animal health company active in four segments of a rapidly growing market. It combines high organic growth, high and improving margins, and an opportunity to grow significantly via acquisitions. We initiate coverage with a BUY and SEK128 target price.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.